ClinicalTrials.gg
CompletedNCT00763971Updated Jun 14, 2021Results posted

Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17

A Phase 3 interventional study of Lisdexamfetamine Dimesylate (LDX) and Methylphenidate Hydrochloride in ADHD, sponsored by Shire. Completed at 49 sites in 10 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-06-14.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity — 1 open to participants now, 1 under way, none of them phase 3. lisdexamfetamine · Attention Deficit Disorder with Hyperactivity.

Enrollment
5th of 51
336 · median 48
Started
2008
with 8 others
Phase 3
15 of 51
none open now
Registered
16th of 51
by date
Lead sponsor
18 of 51
Shire

Among the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, this one is the 5th largest by enrollment, is one of 9 that started in 2008, is one of 15 in phase 3, and was the 16th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

1 of the 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lisdexamfetamine

lisdexamfetamine: first FDA approval 2007 (VYVANSE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies testing lisdexamfetamine in Attention Deficit Disorder with Hyperactivity, or all of them as a file.
02

Study summary

The main aim of this study is to see if giving LDX to children and adolescents aged 6-17 years with ADHD decreases symptoms of ADHD.

03

Conditions studied

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is a male or female aged 6-17 years inclusive at the time of consent.
  2. Subject must meet , Fourth Edition - Text Revision (DSM-IV-TR) criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation.
  3. Subject must have a Baseline ADHD-RS-IV total score ≥28.
  4. Subject has blood pressure measurements within the 95th percentile for age, gender, and height at Screening and Baseline.
  5. Subject is able to swallow a capsule.

Exclusion criteria

Exclusion Criteria:

  1. Subject has failed to respond to more than one adequate course (dose and duration) of stimulant therapy. One course must have been a long-acting formulation.
  2. Subject has a conduct disorder. Oppositional Defiant Disorder is not exclusionary.
  3. Subject is currently considered a suicide risk, has previously made a suicide attempt or has a prior history of, or is currently, demonstrating active suicidal ideation.
  4. Subject has glaucoma.
  5. Subject weighs less than 22.7kg (50lbs).
  6. Subject is significantly overweight based on Centre for Disease Control and Prevention (BMI)-for-age gender specific charts at Screening. Significantly overweight is defined as a BMI >97th percentile for this study.
  7. Subject has a documented allergy, , or intolerance to amphetamine or methylphenidate.
  8. Subject has a documented allergy, hypersensitivity, or intolerance to any in the test or reference products.
  9. Subject has a history of seizures (other than infantile febrile seizures), a tic disorder, or a current diagnosis and/or a known family history of Tourette's Disorder.
  10. Subject has a known history of symptomatic cardiovascular disease, advance arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, or other serious cardiac problems that may place them at increased vulnerability to the sympathomimetic effects of a stimulant drug.
  11. Subject has a known family history of sudden cardiac death or ventricular arrhythmia.
  12. Subject is well controlled on their current ADHD medication with acceptable tolerability.
  13. Subject has a pre-existing severe gastrointestinal tract narrowing (pathologic or iatrogenic).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
336 participants (actual)

Study arms

  • Experimental
    Lisdexamfetamine Dimesylate (LDX)

    Overencapsulated LDX 30, 50, or 70mg

    Drug: Lisdexamfetamine Dimesylate (LDX)

  • Active comparator
    Methylphenidate Hydrochloride

    Overencapsulated Concerta 18, 36, or 54mg

    Drug: Methylphenidate Hydrochloride

  • Placebo comparator
    Placebo

    Overencapsulated Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks

    The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.

    Time frame: Baseline and up to 7 weeks

Secondary outcomes

  1. Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores

    Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

    Time frame: Up to 7 weeks

  2. Change From Baseline in Conner's Parent Rating Scale - Revised (CPRS-R) Total Score at up to 7 Weeks

    The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior.

    Time frame: Baseline and up to 7 weeks

  3. Health Utilities Index-2 (HUI-2) Scores at up to 7 Weeks

    HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.

    Time frame: Baseline and up to 7 weeks

  4. Change From Baseline in the Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at up to 7 Weeks

    The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.

    Time frame: Baseline and up to 7 weeks

  5. Change From Baseline in Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at up to 7 Weeks

    The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.

    Time frame: Baseline and up to 7 weeks

  6. Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at up to 7 Weeks

    The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.

    Time frame: Baseline and up to 7 weeks

  7. Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is a 19-item semi-structured interview designed to capture suicide-related thoughts and behaviors.

    Time frame: Up to 7 weeks

07

Results

Posted Mar 22, 2012

Participant flow

Participant flow — Overall Study
MilestoneLisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlacebo
Started113112111
Completed807442
Not completed333869
Withdrew: Adverse event524
Withdrew: Protocol violation332
Withdrew: Withdrawal by subject455
Withdrew: Lost to follow-up010
Withdrew: Lack of efficacy112254
Withdrew: Unable to swallow capsule211
Withdrew: Personal reason300
Withdrew: Exclusion criteria met100
Withdrew: Sponsor decision100
Withdrew: Due to holiday season201
Withdrew: Randomization error001
Withdrew: Medical monitor decision001
Withdrew: Moved to another country010
Withdrew: Subject wanted dose reduction010
Withdrew: Lack of availability010
Withdrew: Performed final visit on phone010
Withdrew: Participation in 489-326 required100

Outcome measures

PrimaryChange From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks

The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. A decrease in score indicates an improvement in ADHD symptomology.

Time frame:
Baseline and up to 7 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlacebo
Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks-24.3 ± 1.16-18.7 ± 1.14-5.7 ± 1.13
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = <0.001 · Difference in ls means: -18.6 · 95% CI -21.5 to -15.7
  • Methylphenidate Hydrochloride vs Placebo · ANCOVA · p = <0.001 · Difference in ls means: -13.0 · 95% CI -15.9 to -10.2
SecondaryPercentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores

Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.

Time frame:
Up to 7 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
percentage of participantsLisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlacebo
Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores78.060.614.4
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentages: 63.6 · 95% CI 53.0 to 74.1
  • Methylphenidate Hydrochloride vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Difference in percentages: 46.2 · 95% CI 34.6 to 57.7
SecondaryChange From Baseline in Conner's Parent Rating Scale - Revised (CPRS-R) Total Score at up to 7 Weeks

The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true) with a total score ranging from 0 to 81. Higher scores are indicative of increased ADHD. This scale allows parents to respond on the basis of the child's behavior and help assess ADHD and evaluate problem behavior.

Time frame:
Baseline and up to 7 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Conner's Parent Rating Scale - Revised (CPRS-R) Total Score at up to 7 Weeks
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlacebo
Change From Baseline in Conner's Parent Rating Scale - Revised (CPRS-R) Total Score at up to 7 Weeks-24.5 ± 1.70-18.4 ± 1.69-3.2 ± 1.69
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = <0.001 · Difference in ls means: -21.3 · 95% CI -25.5 to -17.0
  • Methylphenidate Hydrochloride vs Placebo · ANCOVA · p = <0.001 · Difference in ls means: -15.1 · 95% CI -19.3 to -10.9
SecondaryHealth Utilities Index-2 (HUI-2) Scores at up to 7 Weeks

HUI is used to describe health status and to obtain utility scores by collecting data using one or more questionnaires in formats selected to match the specific study design criteria. Scoring ranges from 0.00 (dead) to 1.00 (perfect health). Higher scores represent better health status.

Time frame:
Baseline and up to 7 weeks
Reported as:
Mean · Scores on a scale
Health Utilities Index-2 (HUI-2) Scores at up to 7 Weeks
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlacebo
Baseline0.811 ± 0.14510.822 ± 0.13770.806 ± 0.1460
Up to 7 weeks0.878 ± 0.13220.887 ± 0.11510.843 ± 0.1431
SecondaryChange From Baseline in the Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at up to 7 Weeks

The CHIP-CE:PRF evaluates health-related quality of life. It is composed of 5 domains (satisfaction, comfort, resilience, avoidance, and achievement) consisting of a total of 76 items. The global score is an average of the scores for the 5 domains. The majority of items assess frequency of events using a 5-point response format. There is no range for a total score. Raw scale scores are used to generate T-scores. Higher scores indicate better health.

Time frame:
Baseline and up to 7 weeks
Reported as:
Least squares mean · T-scores
Change From Baseline in the Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at up to 7 Weeks
T-scoresLisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlacebo
Change From Baseline in the Child Health and Illness Profile, Child Edition: Parent Report Form (CHIP-CE:PRF) Global T-score at up to 7 Weeks8.6 ± 1.087.1 ± 1.10-0.2 ± 1.07
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = <0.001 · Difference in ls means: 8.8 · 95% CI 6.1 to 11.5
  • Methylphenidate Hydrochloride vs Placebo · ANCOVA · p = <0.001 · Difference in ls means: 7.3 · 95% CI 4.6 to 10.0
SecondaryChange From Baseline in Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at up to 7 Weeks

The WFIRS-P is a 50-item scale with each item scored from 0 (never/not at all) to 3 (very often/very much). Mean scores range from 0 to 3. Higher scores indicate greater functional impairment.

Time frame:
Baseline and up to 7 weeks
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at up to 7 Weeks
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlacebo
Change From Baseline in Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at up to 7 Weeks-0.3 ± 0.04-0.3 ± 0.040.0 ± 0.04
Statistical analysis
  • Lisdexamfetamine Dimesylate (LDX) vs Placebo · ANCOVA · p = <0.001 · Difference in ls means: -0.3 · 95% CI -0.4 to -0.2
  • Methylphenidate Hydrochloride vs Placebo · ANCOVA · p = <0.001 · Difference in ls means: -0.2 · 95% CI -0.3 to -0.1
SecondaryChange From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at up to 7 Weeks

The BPRS-C characterizes psychopathology. A total of 21 items are rated on a scale from 0 (not present) to 6 (extremely severe) with a total score ranging from 0 to 126. A decrease in score indicates a reduction in psychopathology.

Time frame:
Baseline and up to 7 weeks
Reported as:
Mean · Scores on a scale
Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at up to 7 Weeks
Scores on a scaleLisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlacebo
Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at up to 7 Weeks-9.15 ± 11.264-9.71 ± 6.936-2.59 ± 7.436
SecondaryColumbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS is a 19-item semi-structured interview designed to capture suicide-related thoughts and behaviors.

Time frame:
Up to 7 weeks
Reported as:
Number · participants
Columbia-Suicide Severity Rating Scale (C-SSRS)
participantsLisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlacebo
Suicidal ideation100
Non-suicidal self injurious behavior100

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lisdexamfetamine Dimesylate (LDX)—3/111 (2.7%)80/111 (72.1%)
Methylphenidate Hydrochloride—2/111 (1.8%)72/111 (64.9%)
Placebo—3/110 (2.7%)63/110 (57.3%)
Most frequent serious events
Most frequent serious events
EventLisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlacebo
Loss of conciousnessNervous system disorders0/1110/1111/110
HematomaVascular disorders0/1110/1111/110
Clavicle fractureInjury, poisoning and procedural complications0/1110/1111/110
SyncopeNervous system disorders1/1111/1110/110
Gastroesophageal reflux diseaseGastrointestinal disorders1/1110/1110/110
AppendicitisInfections and infestations1/1110/1110/110
OverdoseInjury, poisoning and procedural complications0/1111/1110/110
Most frequent other events
Showing 10 of 28
Most frequent other events
EventLisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlacebo
Decreased appetiteMetabolism and nutrition disorders28/11117/1113/110
HeadacheNervous system disorders16/11122/11122/110
InsomniaPsychiatric disorders16/1119/1110/110
Weight decreasedInvestigations15/1115/1110/110
NasopharyngitisInfections and infestations8/11114/1118/110
NauseaGastrointestinal disorders12/1118/1113/110
AnorexiaMetabolism and nutrition disorders12/1116/1112/110
Abdominal upper painGastrointestinal disorders8/1119/1116/110
CoughRespiratory, thoracic and mediastinal disorders3/1118/1110/110
Initial insomniaPsychiatric disorders3/1117/1111/110

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlaceboTotal
Mean10.9 ± 2.8710.9 ± 2.6311.0 ± 2.8210.9 ± 2.77
Age, Customized
Age, Customized(Participants)Lisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlaceboTotal
6-12 years778079236
13-17 years34313196
Sex: Female, Male
Sex: Female, Male(Participants)Lisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlaceboTotal
Female24211964
Male879091268
Region of Enrollment
Region of Enrollment(Participants)Lisdexamfetamine Dimesylate (LDX)Methylphenidate HydrochloridePlaceboTotal
France1091130
Hungary11101132
Spain13141441
Poland34310
Belgium43411
Netherlands1001
Germany363635107
United Kingdom810927
Italy99725
Sweden18171752
08

Study locations

49 sites
  • ZiekenhuisNetwerk Antwerpen, Commandant Weynsstraat 165, Campus Hoge Beuken
    Hoboken, Antwerp 2660, Belgium
  • Universitair Ziekenhuis Gent, Kinder-en Jeugdpsychiatrie, De Pintelaan 185
    Ghent, East Flanders 9000, Belgium
  • Afdeling Psychiatrie, UZ Herestraat 49, Bus 07003
    Leuven, 3000, Belgium
  • Hospital Archet 2
    Nice, Cedex 03 6202, France
  • Hôpital Robert Debré, Service de Psychopathologie de l'Enfant et de l'Adolescent
    Paris, Ile-De-France 75019, France
  • Centre Hospitalier Charles Perrens, Bordeaux, Service de Psychiatrie de l'Enfant et de l'Adolescent
    Bordeaux Cédex, 33076, France
  • Hôpital Gui de Chauliac, 80, avenue Augustin Fliche
    Montpellier Cedex 05, 34295, France
  • Zentralinstitut für Seelische Gesundheit Mannheim, Klinik für Psychiatrie und Psychotherapie des Kindes-und Jug, J4/J5
    Mannheim, Baden Wuttemburg 68159, Germany
  • Schwerpunktpraxis für Entwicklung und Lernen, Heinrichsdamm 6
    Bamberg, Bayern 96047, Germany
  • Medizinisches Studienzentrum Würzburg, Augustinerstrasse 10
    Würzburg, Bayern 97070, Germany
  • Universität Würzburg, Klinik und Poliklinik fuer Kinder-und Jugendpsychiatrie und Psychotherapie
    Würzburg, Bayern 97080, Germany
  • Universitatsklinikum Gießen und Marburg GmbH, Hans-Sachs-Strasse 4
    Marburg, Hessen 35039, Germany
  • Universitat Gottingen
    Göttingen, Niedersachsen 37075, Germany
  • Klinikum der Johannes Gutenberg-Universität Mainz, Klinik und Poliklinik für Kinder-und Jugendpsychiatrie und-psychotherapie,
    Mainz, Rheinland-Pfalz 55131, Germany
  • Universitätsmedizin Berlin
    Berlin, 13353, Germany
  • Albert-Ludwigs-Universitat Freiburg
    Freiburg, 79104, Germany
  • Praxis Dr. Walter Robert Otto
    Fulda, 36037, Germany
  • Praxis Dr. Wolff
    Hagen, 58093, Germany
  • Praxis Dr. med. Friedrich Kaiser und Dr. med. Ingrid Marinesse
    Hamburg, 22415, Germany
  • Praxis für Neuropädiatrie, Schomburgstrasse 120
    Hamburg, 22767, Germany
  • Vadaskert Kórház és Szakambulancia
    Budapest, 1021, Hungary
  • Pándy Kálmán Kórház
    Gyula, 5700, Hungary
  • Gyermek és Ifjúságpszichiátriai Szakrendelés és Gondozó
    Pécs, 7632, Hungary
  • Szegedi Tudományegyetem
    Szeged, 6750, Hungary
  • Università degli Studi di Cagliari, Dipartimento di Neuroscienze
    Cagliari, 9124, Italy
  • Azienda Ospedaliera Universitaria Policlinico G. Martino
    Messina, 98125, Italy
  • Azienda Ospedaliera della 2 Universita di Napoli
    Napoli, 80131, Italy
  • Academisch Ziekenhuis Maastricht
    Maastricht, 6229 HX, Netherlands
  • Universitair Medisch Centrum Sint Radboud, Reinier Postlaan 10
    Nijmegen, 6525 GC, Netherlands
  • Szpital Uniwersytecki im. dr. Antoniego Jurasza w Bydgoszczy
    Bydgoszcz, Kujawsko-pomorskie 85-094, Poland
  • Wojewodzki Osrodek Lecznictwa Psychiatrycznego
    Torun, Kujawsko-pomorskie 87-100, Poland
  • Samodzielny Publiczny Dzieciecy Szpital Kliniczny
    Warszawa, Mazowieckie 00-576, Poland
  • Gdanski Uniwersytet Medyczna w Gdansku
    Gdansk, Pomorskie 80-282, Poland
  • Hospital Sant Joan de Dèu
    Esplugues de Llobregat, Barcelona 08950, Spain
  • Hospital Marítimo, Unidad de Salud Mental Infanto-Juvenil (USMI-J), Carretera del Sanatorio s/n
    Torremolinos, Malaga 29630, Spain
  • Clínica Universitaria de Navarra, Unidad de Psiquiatría Infantil y Adolescente, Dept. de Psiquiatría y Psicología Médica
    Pamplona, Navarra 31080, Spain
  • Hospital Universitario de Canarias C/Ofra
    San Cristóbal de la Laguna, Santa Cruz De Tenerife 38320, Spain
  • Complejo Hospitalario Universitario de Badajoz
    Badajoz, 6010, Spain
  • Mutua de Terrassa
    Barcelona, 8221, Spain
  • Hospital Ramón y Cajal, Servicio de psiquiatría
    Madrid, 28034, Spain
  • Utvecklingsneurologiska Enheten (UNE), BUC, Lockerudsv 12
    Mariestad, Vastergotland 54224, Sweden
  • Drottning Silvias Barnsjukhus
    Goteborg, 41119, Sweden
  • Astrid Lindgren Children's Hospital, Karolinska University Hospital
    Stockholm, 171 76, Sweden
  • Barn och Ungdomsmedicin klinik Mölnlycke, Ekdalavägen 2,Box 9
    Stockholm, 435 30, Sweden
  • Basildon Hospital, Child Developement Centre, Nethermayne
    Basildon, Essex SS16 5NL, United Kingdom
  • Lighthouse Child Development Centre, Snakes Lane
    Southend-on-Sea, Essex SS2 6XT, United Kingdom
  • Victoria Hospital, Paediatric Unit, Hayfield Road
    Kirkcaldy, Fife, Scotland KY2 5AH, United Kingdom
  • Tayside Childrens Hospital, Clinical Research Facility, Level 4
    Dundee, Scotland DD1 9SY, United Kingdom
  • Ryegate Children's Centre, Tapton Crescent Road
    Sheffield, Yorkshire S10 5DD, United Kingdom
09

References and documents

Publications

  • Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. Eur Neuropsychopharmacol. 2013 Oct;23(10):1208-18. doi: 10.1016/j.euroneuro.2012.11.012. Epub 2013 Jan 15. PubMed 23332456 ↗
  • Coghill DR, Banaschewski T, Lecendreux M, Zuddas A, Dittmann RW, Otero IH, Civil R, Bloomfield R, Squires LA. Efficacy of lisdexamfetamine dimesylate throughout the day in children and adolescents with attention-deficit/hyperactivity disorder: results from a randomized, controlled trial. Eur Child Adolesc Psychiatry. 2014 Feb;23(2):61-8. doi: 10.1007/s00787-013-0421-y. Epub 2013 May 25. PubMed 23708466 ↗
  • Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, Adeyi B, Squires LA, Coghill D. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs. 2013 Oct;27(10):829-40. doi: 10.1007/s40263-013-0095-5. PubMed 23893527 ↗
  • Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder MH. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder. Value Health. 2015 Sep;18(6):824-31. doi: 10.1016/j.jval.2015.06.005. Epub 2015 Aug 20. PubMed 26409610 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2008 to primary completion in Mar 2011, 27 months.

Results were first posted in Mar 2012, 1 year after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 27 months is above that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2008
First posted
Oct 1, 2008
StartActual
Nov 17, 2008
Primary completionActual
Mar 16, 2011
CompletionActual
Mar 16, 2011
Results first posted
Mar 22, 2012
Last update
Jun 14, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00763971
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Oct 1, 2008
Start date
Nov 17, 2008
Primary completion
Mar 16, 2011
Completion
Mar 16, 2011
Results posted
Mar 22, 2012
Last update
Jun 14, 2021

Study contacts

Study Director
study director · Takeda
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lisdexamfetamine

Start the discussion